Rani Therapeutics NASDAQ: RANI outlined progress for its oral biologics delivery platform, including plans to advance its obesity program RT-114 and expectations for additional milestones from its collaboration with Chugai.Chief Executive Officer Talat Imran said the clinical-stage biotechnology company has developed a swallowable device designed to deliver biologic medicines in the small intestine with bioavailability comparable to subcutaneous injection. The RaniPill is intended to administer biologics in ...